BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34409361)

  • 1. A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB).
    Rogers CL; Gibson M; Kern JS; Martin LK; Robertson SJ; Daniel BS; Su JC; Murrell OGC; Feng G; Murrell DF
    JAAD Int; 2021 Mar; 2():134-152. PubMed ID: 34409361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study.
    Bishnoi A; Manjunath S; Kishore K; De D; Handa S; Murrell DF; Mahajan R
    Indian J Dermatol Venereol Leprol; 2022; 88(2):177-183. PubMed ID: 34491666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
    Loh CC; Kim J; Su JC; Daniel BS; Venugopal SS; Rhodes LM; Intong LR; Law MG; Murrell DF
    J Am Acad Dermatol; 2014 Jan; 70(1):89-97.e1-13. PubMed ID: 24355263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB).
    Bruckner AL; Fairclough DL; Feinstein JA; Lara-Corrales I; Lucky AW; Tolar J; Pope E
    Br J Dermatol; 2018 May; 178(5):1128-1134. PubMed ID: 29341069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychometric Properties of the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa patient score (iscorEB-p): a patient-reported outcome measure.
    Salamon G; Strobl S; Field-Werners U; Diem A; Schwieger-Briel A; Pope E
    Br J Dermatol; 2024 Jun; 191(1):75-81. PubMed ID: 38261404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa.
    Paller AS; Pope E; Rudin D; Malyala A; Ramsdell D; Johnson R; Landy H; Murrell DF;
    Orphanet J Rare Dis; 2022 Aug; 17(1):314. PubMed ID: 35964087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa.
    Jain SV; Harris AG; Su JC; Orchard D; Warren LJ; McManus H; Murrell DF
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):692-698. PubMed ID: 27580431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Instrument for scoring clinical outcome of research for epidermolysis bullosa: a consensus-generated clinical research tool.
    Schwieger-Briel A; Chakkittakandiyil A; Lara-Corrales I; Aujla N; Lane AT; Lucky AW; Bruckner AL; Pope E
    Pediatr Dermatol; 2015; 32(1):41-52. PubMed ID: 24650374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translation, cross-cultural adaptation and validation of the Quality of Life Evaluation in Epidermolysis Bullosa instrument in Brazilian Portuguese.
    Cestari T; Prati C; Menegon DB; Prado Oliveira ZN; Machado MC; Dumet J; Nakano J; Murrell DF
    Int J Dermatol; 2016 Feb; 55(2):e94-9. PubMed ID: 26474322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of the prevalence of osteoporosis and osteopenia in patients with epidermolysis bullosa: A cross-sectional study.
    Kang M; Chen JSC; Radjenovic M; Yang A; Feng GHY; Murrell DF
    Exp Dermatol; 2021 Nov; 30(11):1675-1685. PubMed ID: 33347654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America.
    Feinstein JA; Jambal P; Peoples K; Lucky AW; Khuu P; Tang JY; Lara-Corrales I; Pope E; Wiss K; Hook KP; Levin LE; Morel KD; Paller AS; McCuaig CC; Powell J; Eichenfield LF; Price H; Levy ML; Schachner LA; Browning JC; Bayliss S; Jahnke M; Shwayder T; Glick SA; Bruckner AL
    JAMA Dermatol; 2019 Feb; 155(2):196-203. PubMed ID: 30586139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Birmingham Epidermolysis Bullosa Severity score: development and validation.
    Moss C; Wong A; Davies P
    Br J Dermatol; 2009 May; 160(5):1057-65. PubMed ID: 19434791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ophthalmologic Approach in Epidermolysis Bullosa: A Cross-Sectional Study With Phenotype-Genotype Correlations.
    Mellado F; Fuentes I; Palisson F; I Vergara J; Kantor A
    Cornea; 2018 Apr; 37(4):442-447. PubMed ID: 29384803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translation, cultural adaptation and validation of the German Quality of Life in Epidermolysis Bullosa (QOLEB) questionnaire.
    Salamon G; Strobl S; Field-Werners U; Welponer T; Murrell DF; Diem A
    J Health Psychol; 2024 Feb; ():13591053231221369. PubMed ID: 38369713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The severity of malnutrition in children with epidermolysis bullosa correlates with disease severity.
    Manjunath S; Mahajan R; De D; Handa S; Attri S; Behera BN; Bhasin SL; Bolia R
    Sci Rep; 2021 Aug; 11(1):16827. PubMed ID: 34413404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study.
    Mellerio JE; Pillay EI; Ledwaba-Chapman L; Bisquera A; Robertson SJ; Papanikolaou M; McGrath JA; Wang Y; Martinez AE; Jeffs E
    Orphanet J Rare Dis; 2023 Aug; 18(1):235. PubMed ID: 37559055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa.
    Fine JD; Johnson LB; Weiner M; Suchindran C
    Clin Exp Dermatol; 2004 Mar; 29(2):122-7. PubMed ID: 14987264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case Report of the Use of Rituximab and the Epidermolysis Bullosa Disease Activity Scoring Index (EBDASI) in a Patient with Epidermolysis Bullosa Acquisita with Extensive Esophageal Involvement.
    Yang A; Kim M; Craig P; Murrell DF
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):325-328. PubMed ID: 30665483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-centre study on predictors and determinants of pubertal delay and growth impairment in Epidermolysis Bullosa.
    Rodari G; Guez S; Salera S; Ulivieri FM; Tadini G; Brena M; Profka E; Giacchetti F; Arosio M; Giavoli C
    PLoS One; 2022; 17(9):e0274072. PubMed ID: 36067143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life and clinical severity in people with epidermolysis bullosa - A proposal for assessing nutritional compromise by body mass index (Birmingham Epidermolysis Bullosa Severity Score).
    Togo CCG; Zidório APC; Sá NM; Dutra ES
    Nutr Hosp; 2024 Apr; 41(2):400-408. PubMed ID: 38149521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.